Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Can J Cardiol. 2023 Nov;39(11):1686-1694. doi: 10.1016/j.cjca.2023.07.021. Epub 2023 Jul 24.
Although inflammatory biomarkers have been associated with cardiovascular events in nonsurgical settings, these associations have not been systematically addressed in patients undergoing cardiac surgery. This review aimed to evaluate the relationships of inflammatory markers with mortality and adverse cardiovascular events in patients undergoing cardiac surgery.
Medline, Embase, and Central databases were systematically searched for studies reporting pre- or postoperative levels of inflammatory biomarkers in patients undergoing cardiac surgery. Outcomes of interest were postoperative mortality, nonfatal myocardial infarction, stroke, congestive heart failure, and major adverse cardiovascular events (MACE). Studies reporting multivariable adjusted risk estimates were included. Risk estimates were pooled with the use of random-effects models and reported as summary odds ratios (ORs).
Among 14,465 citations identified, 29 studies including 29,401 participants met the eligibility criteria. The average follow-up time after surgery was 31 months. Preoperative C-reactive protein (CRP) levels were associated with an increased risk of all-cause mortality (OR 1.88, 95% CI 1.60-2.20; I = 19%; 11 studies) and MACE (OR 1.73, 95% CI 1.34-2.24; I = 0%; 3 studies). CRP levels measured on postoperative day 6 (OR 7.4, 95% CI 2.90-18.88, 1 study) and day 10 (OR 11.8, 95% CI 3.50-39.78, 1 study) were associated with a higher risk of all-cause mortality. Less, but overall similar, information was available for other inflammatory biomarkers.
In this large meta-analysis, inflammatory biomarkers measured before or after cardiac surgery were associated with mortality and adverse cardiovascular outcomes in patients undergoing cardiac surgery.
尽管在非手术环境中炎症生物标志物与心血管事件相关,但这些关联在接受心脏手术的患者中尚未得到系统研究。本综述旨在评估炎症标志物与接受心脏手术患者的死亡率和不良心血管事件的关系。
系统检索了 Medline、Embase 和中央数据库,以寻找报告接受心脏手术患者术前或术后炎症生物标志物水平的研究。感兴趣的结果是术后死亡率、非致死性心肌梗死、卒中和充血性心力衰竭以及主要不良心血管事件(MACE)。纳入报告多变量校正风险估计的研究。使用随机效应模型汇总风险估计,并报告为汇总优势比(OR)。
在 14465 条引用中,有 29 项研究(共 29401 名参与者)符合入选标准。术后平均随访时间为 31 个月。术前 C 反应蛋白(CRP)水平与全因死亡率(OR 1.88,95%CI 1.60-2.20;I = 19%;11 项研究)和 MACE(OR 1.73,95%CI 1.34-2.24;I = 0%;3 项研究)风险增加相关。术后第 6 天(OR 7.4,95%CI 2.90-18.88,1 项研究)和第 10 天(OR 11.8,95%CI 3.50-39.78,1 项研究)测量的 CRP 水平与全因死亡率风险增加相关。对于其他炎症生物标志物,虽然信息较少,但总体相似。
在这项大型荟萃分析中,心脏手术后测量的炎症生物标志物与接受心脏手术患者的死亡率和不良心血管结局相关。